RxDoctor Payments Data

Daniel Sanchez, MD

Internal Medicine · Ponce, PRNPI 1912994781

Payments from drug & device makers

$3,230in general payments, 2019–2025

Across 49 payments — averaging $65.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Bayer$416
  • Amgen$258
  • Novo Nordisk$256
  • AbbVie$171
  • GSK$143
  • plus $608 from 10 others

What the payments were for

  • Food & beverage$3,230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,230 in reported general payments places this provider in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$25,064
Medicare patients
50
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol132$185,183
OzempicSemaglutide76$96,038
JardianceEmpagliflozin52$62,448
RybelsusSemaglutide29$54,854
KerendiaFinerenone40$48,915
EliquisApixaban38$45,923
XareltoRivaroxaban20$29,877
MounjaroTirzepatide14$29,118
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$24,853
Dexlansoprazole DrDexlansoprazole49$22,814
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$22,328
TradjentaLinagliptin13$18,040
EntrestoSacubitril/Valsartan11$15,498
Tresiba Flextouch U-200Insulin Degludec16$10,323
SymbicortBudesonide/Formoterol Fumarate22$9,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,378$216,957179 claims
Novo NordiskOzempic, Rybelsus$256$150,892105 claims
Boehringer IngelheimJardiance, Tradjenta$75$80,48765 claims
BayerKerendia$416$48,91540 claims
PfizerEliquis$125$45,92338 claims
Johnson & JohnsonXarelto$95$29,87720 claims
Lilly USA, LLCMounjaro$54$29,11814 claims
GSKTrelegy Ellipta$143$24,85322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →